Pyroptosis‑Triggering Lipid Nanoparticles for Targeted Immunogenic Cell Death (Pyroptosis‑Triggering Lipid Nanoparticle, Tech ID: 23‑014)
Technology Overview: This technology introduces lipid nanoparticle (LNP) formulations engineered to trigger pyroptosis, an immunogenic form of programmed cell death. By delivering payloads that selectively activate pyroptotic pathways, the platform enables localized cell destruction while stimulating innate immune responses. The technology is adaptable to cancer immunotherapy, inflammatory disease modulation, and combination therapies with checkpoint inhibitors or biologics.
Industry Pain Point: Many cancer therapies induce non‑immunogenic cell death, limiting durable therapeutic response.
NJIT Solution: These LNPs enable controlled induction of pyroptosis, enhancing tumor cell killing while promoting immune activation.
Key Features & Advantages
- Induces immunogenic cell death (pyroptosis)
- Programmable lipid nanoparticle platform
- Compatible with combination immunotherapies
- Potential for enhanced therapeutic durability
Development Stage: TRL 2–3 – Early preclinical proof‑of‑concept demonstrated.
Target Markets
- Cancer immunotherapy
- Targeted drug delivery platforms
- Immuno‑oncology research
Market Opportunity
- Global cancer immunotherapy market (2026): ~$135B
- CAGR: ~12–14%
- Projected market size (2035): ~$360–380B
Commercial & IP Details
Inventors: William Ho, Fengqiao Li, Xiaoyang Xu